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ABSTRACT
The therapeutic landscape of castration-resistant prostate 
cancer (CRPC) has changed dramatically in the last decade. 
Previously, limited to castration, second-line hormonal 
manipulations, and palliative treatment with mitoxantrone 
plus prednisone, median overall survival (OS) remained 
in the 9-18 months range. With multiple lines of survival 
improving chemotherapies, AR-directed drugs, as well as 
new immunotherapy and bone-directed therapies, median 
OS increased to more than 30 months and quality of life 
increased accordingly. The question remains, as how to 
sequence, and choose the best therapeutic option for each 
individual patient with the current data.
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Introduction
Androgen deprivation is the backbone of therapy for 
advanced prostate cancer, and this treatment leads to 
response in terms of both prostate-specific antigen (PSA) 
responses and clinical improvements in the great majority 
of patients [1]; however, this treatment is not curative and 
the most patients eventually progress to become castration 
resistant. The term ‘hormone-resistance’ is not used 
anymore, since the androgen receptor (AR) still remains an 
important pathway for growth during the castration resistant 
period. Castration-resistant prostate cancer (CRPC) is used 
to describe a heterogeneous group of patients including those 
with/without metastases or symptoms. The Prostate Cancer 
Working Group 2 (PCWG2) defines CRPC as prostate cancer 
progressing despite castrate levels of testosterone (<0.5 ng/
ml); this progression may be biochemical (PSA progression 
only), radiological or symptomatic [2]. 
The therapeutic landscape of CRPC has changed 
dramatically in the last decade. Previously limited to 
castration, second-line hormonal manipulations, and 
palliative treatment with mitoxantrone plus prednisone, 
median overall survival (OS) remained in the 9-18 
months range. With multiple lines of survival improving 
chemotherapies, AR-directed drugs, as well as new 
immunotherapy and bone-directed therapies, median 
OS increased to more than 30 months and quality of life 
increased accordingly [3]. Improvement came in small but 
consistent steps at first and quite giants leaps later on, with 
zoledronic acid leading the initial improvement wave with 
reduction of skeletal-related event (SRE) incidence [4]. The 
TAX 327 study followed in 2004, demonstrating improved 
OS with docetaxel [5]. The SWOG 9916 trial confirmed the 
efficacy of docetaxel, accompanied by extramustine [6]. In 
2010, immunotherapy with sipuleucel-T was approved by 
the US FDA due to prolonged survival in non-metastatic 
or minimally metastatic PSA progressing patients [7]. 
Cabazitaxel, a novel tubulin-binding taxane, followed in 
2011, demonstrating efficacy as second-line chemotherapy 
after docetaxel [8], and denosumab significantly prolonged 
the median time to the first SRE [9]. Between 2011 and 2012, 
AR-directed agents, abiraterone acetate and enzalutamide, 
showed further OS improvements in the post-docetaxel 
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setting [10,11]. In 2013, radium-223, an α-emitting radium 
isotope, was announced to improve survival in the post-
docetaxel setting, in those patients with predominant bone 
metastases [12] as well as delaying time to symptomatic 
skeletal events (SSE). Effective therapies are listed in Table 
I. The question remains, as how to sequence, and choose the 
best therapeutic option for each individual patient with the 
current data.
Table I.  Approved therapies for the treatment of metastatic 
castration-resistant prostate cancer 
Drug Target Effect
Abiraterone 
acetate
CYP17A1
Reduces circulating 
testosterone levels
Cabazitaxel Microtubules Microtubule stabilization, interrupts cell cycle
Denosumab RANKL Decreases bone resorp-tion
Docetaxel Microtubules Microtubule stabilization, interrupts cell cycle
Enzalutamide AR AR receptor antagonism, prevents signaling
Radium-223 Bone Localized radiation
Sipuleucel-T
Ex vivo activation of 
PBMC’s via GM-CSF 
and PAP
T-cell activation
Zoledronic acid Osteoclasts Decreases boneresorption
AR-DIRECTED TREATMENT
Huggins originally described the therapeutic role of 
castration in prostate cancer [13]. Intraprostatic androgen 
levels were found to remain significantly higher despite 
the dramatic reduction of serum testosterone, indicating 
that progression is not always due to true androgen 
independence, but rather to functional adaptation that results 
in continuous AR-mediated signaling despite low levels of 
circulating androgens [14]. Mechanisms, including AR gene 
mutations [15], AR splice variant expressions [16], AR gene 
overexpression [17], increased expression of proteins acting 
as transcriptional co-activators [15], TMPRSS2/ERG fusion, 
PTEN, Nkx3.1, and EGR1 overexpression, and up-regulation 
of the enzymes involved in androgen synthesis, namely 
CYP17 α-hydroxylase and C17–20-lyase (CYP17) [18]. 
Therefore, despite castration levels of androgen, in CRPC, 
the AR signaling pathway remains active. Mechanisms of 
castration resistance are depicted in Figure 1. Consequently, 
new agents have been developed in order to interfere with 
the AR pathway or to inhibit CYP17 in order to potently 
block androgen synthesis.
 
Figure 1. Mechanisms of Castration Resistance [14] 
Abiraterone
Abiraterone is a steroidal agent that selectively and 
irreversibly inhibits the CYP17A1 microsomal enzyme, 
encoded by the CYP17A1 gene, which has two distinct 
activating properties: one is its 17-α-hydroxylase property, 
which catalyzes the 17-α-hydroxylation of C21 steroids 
that are necessary for the synthesis of cortisol in the adrenal 
gland [19] and the other is its 17,20-lyase property, which 
catalyzes the scission of the C17–21 bond, converting C21 
compounds to C19 steroids in the sex steroid synthesis 
pathway in the both adrenal gland and the testis [20].
Inhibition of CYP17 results in cortisol deficiency and 
consequent upregulation of the hypothalamic–pituitary–
adrenal pathway with elevated levels of adrenocorticotropic 
hormone. Elevated ACTH generates a syndrome of 
secondary mineralocorticoid excess characterized by fluid 
retention, hypertension and hypokalemia, which often require 
intervention. In order to prevent this side effect, abiraterone is 
usually administered together with prednisone [21].
Initial phase II trials demonstrating the efficacy of 
abiraterone after docetaxel was followed by a large, 
randomized, double-blind Phase III trial (COU-AA-301), 
which, using a 2:1 randomization, 1195 docetaxel-refractory 
CRPC patients received either abiraterone 1 g/daily or 
placebo; both arms received prednisone 5 mg twice daily. 
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The study was unblinded at the time of the first interim 
analysis because of an OS improvement of 3.9 months 
favoring abiraterone (14.8 vs. 10.9 months; hazard ratio 
[HR]: 0.646; 95% CI: 0.54–0.77; p < 0.001) [10]. An 
updated OS analysis conducted before crossover showed 
a median OS improvement of 4.6 months (HR: 0.74; 95% 
CI: 0.64–0.86; p < 0.0001) [22]. Abiraterone also improved 
time to PSA progression (8.5 vs. 6.6 months; p < 0.0001), 
radiographic PFS (rPFS; 5.6 vs. 3.6 months; p < 0.0001), 
with 50% PSA declines (confirmed: 29.5 vs. 5.5%; p < 
0.0001) [22]. Survival improvement was consistent across all 
age groups, prior number of chemotherapy regimens, type of 
progression (PSA vs. radiographic), the absence or presence 
of pain. Benefit was marginal in patients with visceral 
metastases, and performance status >2. Mineralocorticoid-
related adverse events, including fluid retention (31% vs. 
22% placebo; P < 0.001) and hypokalemia (17% vs. 8% 
placebo), were more frequently reported in the Abiraterone 
acetate–prednisone group than in the placebo–prednisone 
group. There was a non-significant increase in grade 1–2 
cardiac events in the treatment group (13% vs. 11% placebo). 
Abiraterone acetate is now considered standard of care for 
patients following chemotherapy. 
A large phase III trial (COU-AA-302) randomized almost 
1000 patients with asymptomatic or minimally symptomatic 
CRPC in the pre-chemotherapy setting, to either abiraterone 
and prednisone or prednisone alone; the primary end points 
were rPFS and OS [23]. Abiraterone significantly improved 
rPFS (16.5 vs. 8.2 months; HR: 0.52; 95% CI: 0.45–0.61; 
p < 0.0001). It also showed a trend towards improved OS 
(median not reached, vs. 27.2 months for prednisone alone; 
HR 0.75; 95% CI, 0.61 to 0.93; P = 0.01). Abiraterone–
prednisone showed superiority over prednisone alone with 
respect to time to initiation of cytotoxic chemotherapy (25.2 
vs. 16.8 months, p-value <0.001) opiate use for cancer-
related pain (not reached vs. 23.7 months, p-value <0.001), 
prostate-specific antigen progression (11.1 vs. 5.6 months, 
p-value <0.001), and decline in performance status (12.3 vs. 
10.9 months, p-value 0.005) [23, 24]. Based on these data, 
the FDA and EMA approved abiraterone for the management 
of both docetaxel-naive and docetaxel pre-treated patients.
Toxicity profile: The main adverse events of 
Abiraterone are related to excess mineralocorticoid, which 
includes fluid retention (33%) and hypokalemia (18%). 
This is due to the inhibition of 17 alpha hydroxylase, which 
causes a compensatory rise in ACTH. Abiraterone should be 
administered with prednisone daily and monthly potassium 
and blood pressure monitoring is essential during treatment. 
While co-administration of prednisone is manageable, long-
term use in earlier disease phases could be problematic due 
to the potential adverse events. These include diabetes, 
weight gain, Cushing syndrome and osteoporosis. Fatigue, 
joint swelling, edema, cough, vomiting, elevated liver 
enzymes, hyperglycemia and hypercholesterolemia have 
also been reported.
In a recent retrospective study, Peer et al. found abiraterone 
to be superior to ketoconazole in the treatment of docetaxel 
refractory mCRPC. PSA response was 46% in the abiraterone 
group vs. 19% in the ketoconazole group (OR 4.3, P = 0.04), 
median biochemical progression free survival (PFS) 7 vs. 2 
months (HR 1.54, P = 0.02), median radiological PFS 8 vs. 2.5 
months (HR 1.8, P = 0.043), median OS 19 vs. 11 months (HR 
0.53, P = 0.79) and treatment interruption due to severe adverse 
events 8% (n = 2) versus 31% (n = 8) (0R 0.6, P = 0.023).
Orteronel
Orteronel (TAK-700) is a CYP17 inhibitor with relative 
selectivity for 17,20-lyase over 17-α-hydroxylase. This 
selectivity improves the drug safety profile when compared 
with agents inhibiting both enzymes in testosterone synthesis. 
TAK-700 has fewer mineralocorticoid effects than abiraterone, 
omitting the need for prednisone, and making orteronel an 
attractive drug for long-term therapy. Phase I/II trials, TAK-
700 showed promising results at 300-400 mg twice daily 
[25]. Two ongoing randomized, placebo-controlled Phase 
III trials are evaluating orteronel in patients with progressive 
CRPC who are either chemotherapy naive (NCT01193244) 
or pretreated with docetaxel (NCT01193257). The post-
docetaxel trial was recently unblinded and terminated at the 
interim analysis because orteronel plus prednisone did not 
meet the primary end point of improved OS when compared 
with placebo (HR: 0.886; p = 0.1898) [26]. Orteronel, 
however, did provide a benefit in radiographic progression 
free survival rates in both chemotherapy naive and post-
chemotherapy mCRPC [26, 27]. 
Enzalutamide (Xtandi®)
Enzalutamide (formerly MDV300) is an oral, second-
generation androgen receptor antagonist that competitively 
inhibits androgen binding to the AR. In contrast to the 
first generation anti-androgens such as flutamide and 
bicalutamide, enzalutamide binds to the receptor with 
greater affinity. Enzalutamide may induce a conformational 
change in AR distinct from that induced by bicalutamide 
making it more efficacious in inhibiting the translocation 
of AR to the nucleus and its DNA interaction. In a phase 
I-II study, 140 men including 78% with mCRPC received 
doses ranging from 30–600mg daily. PSA responses were 
observed in 62% of the chemotherapy naïve patients and 
51% in docetaxel treated patients [29]. 22% of the patients 
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had a soft tissue response and 56% of the patients with bone 
disease had stabilized bone disease. The maximum tolerated 
dose was determined to be 240 mg daily. The median rPFS 
was 56 weeks and 24 weeks in the chemotherapy naïve and 
the chemotherapy pretreated group, respectively.
Enzalutamide was approved after the publication of a 
phase III, double-blind placebo-controlled randomized trial 
by Scher et el (AFFIRM TRIAL) in which 1199 men with 
mCRPC were randomized after chemotherapy to placebo 
vs. oral enzalutamide at a dose of 160 mg per day [30]. The 
median OS was 18.4 months in the enzalutamide group versus 
13.6 months in the placebo group (P < 0.001). The secondary 
endpoints including the PSA- level response rate (54% vs. 
2%), soft tissue response rate (29% vs. 4%), the time to PSA 
progression (8.3 vs. 3 months), rPFS (8.3 vs. 2.9 months), time 
to the first skeletal event (16.7 vs. 13.3 months), quality of life 
response rate (43% vs. 18%), pain palliation achieved in (45% 
vs. 7%) showed significant improvement in the enzalutamide 
group. The enzalutamide group had higher incidence of 
fatigue, hot flashes, musculoskeletal pain and headaches. 
Hypertension was seen in 6.6% in the enzalutamide group vs. 
3.3% in the placebo group. Seizures were reported in 0.6% in 
the enzalutamide group vs. placebo.
The results of the large phase III randomized trial 
(PREVAIL trial) were recently presented at the 2014 
Genitourinary Cancer Symposium [31]. In the PREVAIL 
study, 1,717 chemotherapy naïve patients with mCRPC 
were assigned to receive 160 mg/day of enzalutamide vs. 
placebo in a double blind fashion. After a median follow-
up of 20 months, interim analysis showed that enzalutamide 
significantly reduced the risk of death by 29% (HR 0.706, 
95% CI 0.60–0.84, p <0.0001) and decreased the risk of 
radiographic progression by 81% (HR 0.186, 95% CI 0.15–
0.23, P < 0.0001). 59% of the patients in the enzalutamide 
group had a soft tissue response compared with 5% in the 
placebo arm. Enzalutamide also delayed the median time 
to chemotherapy initiation by 17 months as compared to 
placebo. The patients on the placebo arm needed to start 
cytotoxic chemotherapy after a median of 10.8 months due 
to disease progression. Median time to PSA progression 
was 2.8 months in the placebo group vs. 11.2 months in 
the enzalutamide group. The adverse effects included 
grade 1–2 fatigue (36% vs. 26%), back pain (27% vs. 22%) 
constipation (22% vs. 17%) and arthralgia (20% vs. 16%) 
in the enzalutamide vs. placebo group. The patients with a 
history of seizure disorders were excluded from the trial.
Enzalutamide has been approved by the FDA for the 
treatment of CRPC both before and after docetaxel.
Toxicity profile: Enzalutamide is reported to cause 
fatigue (11%), hot flashes (20%), headache (12%), nausea, 
diarrhea, constipation and musculoskeletal pain. Other 
reported adverse events include hyperglycemia, weight gain 
and glucose intolerance. Seizure was reported in 0.6% of 
the enzalutamide group at 360 to 600 mg doses. Thus, the 
maximum tolerated dose (MTD) is 240 mg/day.
Galeterone (TOK-001) works by disrupting multiple 
androgen signaling pathways simultaneously and by down 
regulating the androgen receptor [32]. ARMOR 1 was a 
multicenter dose escalation study of Galeterone for the 
treatment of chemotherapy naïve non-metastatic prostate 
cancer and mCRPC [33]. The data from ARMOR 1 were 
presented at the 2012 AACR and 2012 ASCO meetings, 
showed that the drug is well tolerated. ARMOR2 is an 
ongoing phase II multicenter trial to evaluate the efficacy 
and safety of Galeterone in the following populations - 
metastatic treatment naïve patients, non-metastatic treatment 
naïve patients, patients who have progressed on Abiraterone 
and patients who have progressed on Enzalutamide. The 
primary endpoints of the study are reduction in PSA levels 
and safety. The secondary endpoints include tumor response 
by the Response Evaluation Criteria in Solid Tumors 
(RECIST), AR modulation and levels of circulating tumor 
cells and markers of CYP17lyase inhibition [34]. 
 ARN509 is a small molecule that is structurally similar 
to enzalutamide. It inhibits both AR nuclear translocation 
and AR binding to DNA [34]. In contrast to bicalutamide, 
it exhibits no agonist activity in prostate cancer cells that 
over express AR. In a preliminary study, among 46 men with 
mCRPC, 26 were treatment naïve and 21 had prior treatment 
with abiraterone. At 12 weeks, the PSA response was 88% 
in the treatment naïve and 29% in the prior-treatment group 
[35]. The toxicity profile included fatigue (38%), nausea 
(29%) and pain (24%). Currently, a phase II multicenter 
study (NCT01171898) is evaluating the activity of ARN-
509 in three different populations of men with mCRPC (high 
risk non-metastatic CRPC, metastatic treatment naïve CRPC 
and progressive disease after abiraterone acetate) and further 
phase III trials are planned.
CHEMOTHERAPY in CRPC
Taxanes
Taxanes bind to different sites on the intracellular β-tubulin 
subunit of microtubules and promote tubulin assembly into 
microtubules. These microtubule bundles act in the mitotic 
phase of the cell cycle and impair the natural dynamics of 
microtubules, leading the cancer cell to mitotic block and 
apoptosis. Furthermore, the suppression of microtubule 
dynamics enhances p53 nuclear accumulation, thereby 
promoting the activation of the p53 downstream target genes. 
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Several preclinical studies suggest that taxanes also have 
anti-angiogenic effects, and inhibit the nuclear accumulation 
of AR, as its trafficking is microtubule dependent. Therefore, 
taxanes may have AR-directed effect on CRPC as well as 
cytotoxic efficacy.
Docetaxel
The TAX 327 study was the first to show a survival benefit 
with chemotherapy in CRPC. In the study, 1006 patients 
with CRPC were randomized to three-arms, in order to 
compare two dose schedules of docetaxel (75 mg/m2 every 
3 weeks or 30 mg/m2 weekly for 5 of every 6 weeks) plus 
prednisone versus mitoxantrone 12 mg/m2 every 3 weeks 
plus prednisone. The median OS with docetaxel every 3 
weeks was 19.2 months, compared with 16.3 months for 
patients in the control arm (p < 0.004). Weekly docetaxel did 
not result in a significant survival benefit (17.8 months) [37]. 
Treatment was also associated with significant improvement 
in pain and PSA decline. There were no significant 
differences between the two docetaxel arms in terms of 
response rates. The most common toxicity neutropenia, 
occurred more frequently in the every-3-week docetaxel 
regimen vs. mitoxantrone (32 vs. 22%; p < 0.005) [5]. 
The SWOG 99-16 trial acted as a confirmatory trial, 
randomizing 770 patients to docetaxel 60 mg/m2 every 3 
weeks plus estramustine 280 mg orally three-times daily 
on days 1–5 or mitoxantrone 12 mg/m2 every 3 weeks 
plus prednisone 5 mg orally twice daily continuously. The 
docetaxel and estramustine had a significant improvement in 
median OS (17.5 vs. 15.6 months; p = 0.02), longer PFS (6 vs. 
3 months; p< 0.001) and superior median PSA declines [6]. 
Based on the survival benefit observed in the TAX 327 
trial, the FDA and EMA granted approval for docetaxel 75 
mg/m2 every 3 weeks in combination with prednisone as a 
front-line therapy for mCRPC.
Docetaxel re-challenge has never been tested in a phase 3 
trial and lacks survival benefit data. The clinical benefit data 
is mostly retrospective. In a Phase II clinical trial in a group 
of pretreated patients with CRPC, it was demonstrated that 
docetaxel retreatment preserves antitumor activity and is 
well tolerated [38]. Docetaxel re-challenge, once popular in 
the era of no treatments with demonstrated survival benefit, 
must be considered carefully today, for fear of delaying 
effective treatment choices.
The clinical setting of pre-docetaxel and post-docetaxel 
treatments were designated to introduce new drugs into 
the armamentarium of CRPC, acquire approval and 
reimbursement. This clinical classification has recently 
been further disrupted by the announcement of the ground-
breaking results of the CHAARTED trial (ECOG E3805) 
[39]. For patients with metastatic hormone-sensitive 
prostate cancer, upfront chemotherapy with docetaxel, given 
at the same time as hormone therapy at diagnosis instead 
of later, prolongs survival. This finding has been described 
as “practice-changing” and “transformative”. The study 
evaluated 790 men with metastatic hormone-sensitive 
prostate cancer who received androgen-deprivation therapy 
(ADT). Of this cohort, 397 were randomized within 4 
months of starting ADT to receive docetaxel 75 mg/m² every 
3 weeks for 6 cycles. In accordance with the current standard 
of care, the 129 patients who progressed on ADT alone 
were eventually given docetaxel, thus providing crossover 
to the treatment arm. Preliminary results showed fewer 
deaths with ADT plus docetaxel than with ADT alone (104 
vs. 137), and median OS was longer with the combination 
(57.6 vs. 44.0 months; hazard ratio [HR], 0.47; P = .0003) 
[39]. The number of patients who had a significant and 
major suppression of their PSA level was doubled with the 
combination. Median time to progression — an elevation 
in PSA level, new symptoms, or worsening scans — was 
significantly longer with the combination than with ADT 
alone (20.7 vs. 14.7 months; P < .001), as was median time 
to the harder end point of clinical progression (32.7 vs. 19.8 
months; P < .001).
The combination, compared with ADT alone, was 
particularly effective in the 520 men with high-volume 
disease, where the increase in survival was 17 months 
(median overall survival, 49.2 vs. to 32.2 months; HR, 
0.60; P = .0006). Benefit has not yet been observed in the 
low volume disease group since they have not reached the 
median survival yet, but there is a similar trend observed. 
The upfront use of docetaxel in non-CRPC metastatic 
disease is expected to cause a major change in treatment 
algorithm and treatment sequencing, raising new questions 
to be answered through randomized trials.
Cabazitaxel
Resistance to taxanes is primarily associated with increased 
expression of the MDR1 gene that encodes P-glycoprotein, 
an ATP-dependent drug efflux pump that decreases the 
intracellular concentration of these drugs. Cabazitaxel is 
a 7,10-dimethyloxy derivative of docetaxel [40] and, due 
to the presence of these extra methyl groups, is effective 
in docetaxel-resistant tumors because of a poor affinity 
for P-glycoprotein. The extra methyl groups also confer 
on cabazitaxel the unique ability to cross the blood–brain 
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barrier. In phase I trials, cabazitaxel at a dose of 25 mg/m2 
was well tolerated; the most frequently reported adverse 
events were low-grade diarrhea (52%), nausea (40%) and 
vomiting (16%). The dose-limiting toxicity was grade 4 
neutropenia [41]. 
 The Phase III trial (TROPIC) established the efficacy 
and safety of cabazitaxel in 755 patients with progressive 
mCRPC on or after being treated with docetaxel [8]. 
Patients received oral prednisone 10 mg daily and were 
randomly assigned to receive either 12 mg/m2 mitoxantrone 
intravenously or 25 mg/m2 cabazitaxel intravenously every 
3 weeks. Cabazitaxel-treated patients had a median OS 
of 15.1 versus 12.7 months in the mitoxantrone-treated 
patients (HR: 0.70; p < 0.001). Similarly, the median PFS, 
PSA response rate, median time to PSA progression, tumor 
response and time to tumor progression were all improved 
in the cabazitaxel arm [8]. However, pain control and time 
to pain progression were similar in the two treatment arms. 
The survival advantage was independent across tumor grade 
and duration of prior ADT. The most common toxicity 
associated with cabazitaxel was grade 3–4 neutropenia, 
which occurred in 82% of patients, while febrile neutropenia 
was documented in 8% of patients. The non-hematological 
toxicities included diarrhea, fatigue, asthenia and peripheral 
neuropathy. Based on these data, the FDA and EMA granted 
approval for cabazitaxel in mCRPC patients whose disease 
progresses during or after docetaxel treatment.
Molecular determination of resistance to AR-directed 
therapies
The choice of sequencing today depends on clinical factors 
at the discretion of the clinician. It is evident from trials that 
approximately one third of patients have primary resistance 
to AR-directed treatment. The only predictive factor for 
resistance is the prior duration of response to ADT, with 
chemotherapy the choice of treatment, if the ADT duration 
is less than 1 year. AR-directed therapy is not successful 
in patients with short duration of response to ADT, while 
Cabazitaxel is effective independent of the ADT duration. 
We need biomarkers to lead the choice of sequencing 
therapies. One promising data concerns the use of AR 
splice variant AR-V7 to decide on the use of abiraterone or 
enzalutamide. AR, encoded by the splice variant 7, does not 
carry the ligand-binding domain targeted by enzalutamide and 
abiraterone, but remains active as a transcription factor. A pilot 
trial testing the presence of AR-V7 in the circulating tumor 
cells of 62 patients receiving enzalutamide or abiraterone 
and correlating this finding with response has shown that the 
presence of AR-V7 clearly indicates resistance to AR-directed 
therapy [42]. Figure 2 displays the correlation of PSA response 
to AR-V7 presence. Both PSA progression-free survival and 
clinical progression-free survival were significantly better in 
the AR-V7 negative patients. 
Another preliminary study has found that the presence 
of AR-V7 does not influence response to chemotherapy. 
The value of AR-V7 as a predictor of hormone resistance 
remains to be prospectively tested in larger trials.
Treatment Phase III trial Indication Sample size (n) Control arm Primary end point Secondary end points
Z4 iv. or Z8 
iv. → 4 mg
Zoledronic Acid 
Prostate Cancer 
Study
mCRPC 643 Placebo
SRE rate (Z4 vs Z8 → 4 
mg vs P): 38 vs 41 vs 49% 
(p [Z4 vs P] = 0.028)
Time to first SRE (Z4 vs Z8 → 4 mg 
vs P): 488 vs 363 vs 321 days (HR [Z4 
vs P]: 0.68; p = 0.009); mean annual 
incidence of SREs (Z4 vs Z8 → 4 mg 
vs P): 0.77 vs 1.05 vs 1.47 (p [Z4 vs 
P) = 0.005); BPI (mean least squares 
change from baseline value; Z4 vs Z8 
→ 4 mg vs P): 0.58 vs 0.54 vs 1.05 (p 
(Z4 vs P] = 0.024)
Denosumab 
120 mg sc. 
q4w
NCT
00321620
mCRPC, 
zoledronic 
acid naive
1904
Zoledronic 
acid 4 mg 
q4w
Time to first SRE: 20.7 vs 
17.1 months (HR: 0.82; 
p = 0.0002 for nonin-
feriority; p = 0.008 for 
superiority)
Time to first and subsequent SRE rate 
ratio: 0.82 (p = 0.008)
Radium-223 
50 kBq/kg 
q4w
ALSYMPCA mCRPC 921 Placebo OS: 14.9 vs 11.3 months (HR: 0.70; p < 0.001)
Time to first SSE: 15.6 vs.9.8 months 
(HR: 0.66; p < 0.001); time to ALP 
increase: 7.4 vs 3.8 months (HR: 0.17; 
p < 0.001); time to PSA progression: 
3.6 vs 3.4 months (HR: 0.64; p < 
0.001)
Table II.  Summary of bone-targeting and bone metastasis-targeting agents that are approved in metastatic castration-resistant prostate cancer
ALP: Alkaline phosphatase; BPI: Brief Pain Inventory; HR: Hazard ratio; iv.: Intravenous; mCRPC: Metastatic castration-resistant prostate 
cancer; P: Placebo; PSA: Prostate-specific antigen; q3w: Every 3 weeks; q4w: Every 4 weeks; sc.: Subcutaneous; SRE: Skeletal-related 
event; SSE: Symptomatic skeletal event; Z4: Zoledronic acid 4 mg every 3 weeks; Z8: Zoledronic acid 8 mg every 3 weeks.
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Figure 2. Correlation of PSA response to AR-V7 presence [42]
BONE-TARGETING & BONE METASTASIS-
TARGETING AGENTS
Metastatic cancer cells in the bone microenvironment release 
a number of cytokines and growth factors that induce an 
alteration of bone resorption/formation processes, resulting 
in lytic bone lesions, blastic bone lesions or both. Although 
metastatic bone lesions from prostate cancer are typically 
osteoblastic, osteolysis is also a common feature, caused by 
secondary hyperparathyroidism due to the so-called ‘hungry 
bone syndrome’ and by androgen deprivation-induced 
osteoporosis. Due to bone loss, CRPC patients with bone 
metastases commonly experience SREs. If the disease is 
androgen sensitive, SREs are rare. However, SREs become 
frequent in CRPC [43].
Zoledronic Acid
Zoledronic acid, a powerful third-generation nitrogen-
containing bisphosphonate, was the first agent to be 
approved for the management of bone metastases in patients 
with CRPC (44). A Phase III placebo-controlled trial of 
zoledronic acid 4 mg every 3 weeks versus placebo in 643 
patients with mCRPC showed a reduced incidence of SREs; 
44% of patients in the placebo group experienced a SRE 
compared with 33% in the experimental group (p = 0.021). 
Zoledronic acid also significantly increased the time to first 
SRE (488 vs. 321 days; p = 0.009). Pain scores and the use 
of analgesic drugs favored zoledronic acid, but there were 
no differences in either disease progression or OS [4]. 
Denosumab
The RANK/RANKL pathway plays a central role in bone 
resorption regulation. RANKL is part of the TNF family and 
is produced by osteoblasts. RANKL is able to bind RANK 
on the surface of both osteoclast precursors and osteoclasts, 
inducing osteoclast maturation, survival and activity [44]. 
Denosumab is a fully human monoclonal antibody against 
RANKL; preventing RANKL from activating its receptor, 
RANK, thus inhibiting osteoclast formation, function and 
survival, decreasing bone resorption and increasing bone mass 
and strength in both cortical and trabecular bone [9]. When 
compared with zoledronic acid in a Phase III trial that enrolled 
1904 patients with mCRPC to the bone, denosumab at 120 
mg every 28 days improved the median time to first SRE by 
3.6 months (HR: 0.82; p = 0.008). The two groups had similar 
OS and time to disease progression. Adverse event rates were 
also similar, with the exception of an increased incidence of 
hypocalcemia (13% in the denosumab group vs. 6% in the 
zoledronic acid group; p < 0.0001). Denosumab has been 
approved by the FDA and EMA for the treatment of mCRPC 
patients with bone metastases.
Radium-223 Dichloride
Radium-223 is a targeted α-emitter that acts as calcium 
mimetic and selectively binds areas of new bone growth in 
and around bone metastases. Unlike β-emitting agents that 
are myelotoxic, radium-233 emits ionizing radiation with 
high energy and extremely short penetration (<100 µm; 
2–10 cell diameters), causing highly localized tumor cell 
killing with minimal side effects to normal cells [45].
 The FDA and EMA recently approved radium-223 for 
the treatment of patients with CRPC and symptomatic bone 
metastases on the basis of the results of the ALSYMPCA 
trial [12]. This Phase III placebo-controlled trial assessed 
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the efficacy and safety of radium-223 in patients with CRPC 
and symptomatic bone metastases pretreated with or unfit 
for docetaxel. The primary end point was OS; secondary 
end points included time to first SSE, time to an increase in 
alkaline phosphatase or PSA levels and safety. 921 patients 
were randomized with an allocation ratio of 2:1 to receive 
radium-223 at a dose of 50 kBq/Kg administered as six 
injections at 4-weekly intervals or placebo. Radium-223 
was well tolerated and significantly improved OS by 30% 
(14.9 versus 11.3 months; HR: 0.70; 95% CI: 0.58–0.83; p < 
0.001) and delayed time to first SSE [12]. 
IMMUNOTHERAPY
Prostate cancer is an attractive target for therapeutic cancer 
vaccines because it expresses a number of tumor-associated 
antigens and exhibits slow growth, which could allow the 
immune system to have sufficient time to induce an effective 
antitumor immune response. In addition, disease recurrence 
is often diagnosed early (with many patients only having 
biochemical progression) and there is a biological marker 
that is able to detect early relapse (PSA and PSA doubling 
time) [46].
Sipuleucel-T
Sipuleucel-T is a cellular immunotherapy aimed at 
stimulating an immune response against a widely expressed 
prostate cancer antigen, prostatic acid phosphatase, fused 
with GM-CSF. Efficacy of sipuleucel-T was demonstrated 
in three randomized, double blind, controlled, multicenter 
Phase III studies (D9901, D9902A and D9902B) that 
enrolled a total of 737 patients. An integrated analysis of 
two of the studies – D9901 and D9902A– showed that 
sipuleucel-T provided OS benefit compared with placebo 
(23.2 vs. 18.9 months; p = 0.011) [47]. 
The IMPACT study (D9902B) included patients with 
asymptomatic or minimally symptomatic chemotherapy-
naive mCRPC, predominantly with rising PSA (7). 512 
patients were randomized to sipuleucel-T (n = 341) versus 
placebo (n = 171) in a 2:1 ratio. The primary end point was 
met, with a median OS improvement for the experimental 
arm of 4.1 months (25.8 vs. 21.7 months; p = 0.03). 
However, there was no significant effect on PSA response 
rate, radiologic responses or time to progression. Sipuleucel-
T-related toxicities were mainly infusion-related chills, 
nausea, fever, headache and fatigue. This trial led to FDA 
approval for the treatment of asymptomatic or minimally 
symptomatic mCRPC, but treatment costs and complicated 
reimbursement strategies have limited its use.
PROSTVAC®-VF
PROSTVAC®-VF (Bavarian Nordic, Kvistgaard, Denmark) 
is a recombinant vaccine consisting of two vectors encoding 
PSA and three immune co-stimulatory agents, administered 
with a fowlpox viral boost. In a Phase II, randomized, double 
blind, placebo-controlled trial, 125 patients with minimally 
symptomatic mCRPC were randomized 2:1 to PROSTVAC-
VF or control empty vectors. Patients randomized to the 
immunotherapy received a priming dose of PROSTVAC-V, 
followed by six booster doses administered with low-dose 
GM-CSF. The primary end point was PFS, which was 
similar in the two groups (p = 0.6). However, median OS 
in the immunotherapy-treated group was improved (25.1 vs. 
16.6 months; HR: 0.56; p = 0.0061) [48]. 
 PROSTVAC-VF is currently being tested in a Phase III 
trial (NCT01322490) in which patients are randomized to 
three treatment groups: PROSTVAC-VF, vaccine plus GM-
CSF or vector placebo control. The primary end point of 
this study is OS and it is statistically powered to detect 18% 
differences in the HRs for all between-group comparisons.
Ipilimumab
Ipilimumab is a human monoclonal antibody that enhances 
and prolongs T-cell activation by blocking immune 
checkpoint CTLA-4 receptors found on the surface of T cells. 
In a randomized Phase II trial, 108 patients with advanced 
prostate cancer treated with ipilimumab plus androgen-
deprivation therapy were more likely to have undetectable 
PSA levels by 3 months compared with those treated with 
endocrine therapy alone (55 vs. 38%). Ipilimumab has been 
tested against placebo with radiation treatment [49], and 
also following bone-directed radiation therapy in patients 
with CRPC previously treated with docetaxel [50]. These 
studies did not meet their endpoints of OS. Prespecified 
subset analyses suggest that ipilimumab may be most active 
in patients with favorable laboratory prognostic factors (e.g., 
decreased alkaline phosphatase or elevated hemoglobin 
level) or in patients without visceral disease. 
SEQUENCING & COMBINATIONS
We are thankful for the appearance of many effective 
therapeutic strategies in CRPC, but now are faced with 
the challenge of sequencing treatments in each individual 
patient. There is even less data for combination of these 
therapeutic approaches. Factors to be considered in decision-
making are the patient’s clinical status (e.g., asymptomatic 
or symptomatic), rate of disease progression and disease 
burden, presence of bone or visceral metastases, mechanism 
of action, tolerability and side effects, prior treatments and 
response.
For docetaxel-untreated patients, abiraterone and 
enzalutamide both represents valid therapeutic options for 
asymptomatic or minimally symptomatic mCRPC patients 
without visceral disease. Since AR-directed therapy is 
effective before docetaxel, the next question is whether 
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subsequent docetaxel efficacy may be reduced. Preclinical 
and clinical data suggest a partial cross-resistance between 
taxanes and AR-directed agents, possibly due to the effect 
of taxanes on the AR pathway. Prostatic carcinoma cells 
after CYP17 inhibitor treatment could undergo biological 
changes and become chemotherapy resistant due to cross-
resistance between AR-directed drugs and taxanes [51]. 
A small study demonstrated lower docetaxel activity in 
abiraterone-refractory patients [52]. Recently, Schweizer et 
al. retrospectively explored the efficacy of docetaxel after 
abiraterone treatment in 119 CRPC patients [53]. Patients 
who received abiraterone before docetaxel chemotherapy 
had worse PSA responses (38 vs. 63%; p = 0.02), shorter 
median PSA PFS (4.1 vs. 6.7 months; p = 0.002) and worse 
median PFS (4.4 vs. 7.6 months; p = 0.003). Multivariable 
analysis showed that prior abiraterone treatment was an 
independent predictor of shorter PSA PFS (HR: 3.48; 95% 
CI: 1.36–8.94; p = 0.01) and PFS (HR: 3.62; 95% CI: 1.41–
9.27; p = 0.008) [52].
Sipuleucel-T seems to be a valid option for carefully 
selected patients with asymptomatic disease, but loses its 
feasibility through cost and availability issues. 
   Docetaxel is the treatment of choice for patients with 
visceral metastases from mCRPC and symptomatic mCRPC 
in the chemotherapy-naive setting. Docetaxel also represents 
the first treatment choice for patients with asymptomatic 
disease but a rapid PSA doubling time. It is effective in 
both patients with symptomatic disease and those with 
asymptomatic disease. 
For patients who have been pretreated with docetaxel, 
there are currently three therapeutic options: cabazitaxel, 
abiraterone and enzalutamide. All these three drugs have 
been demonstrated to be successful in improving OS after 
docetaxel failure. Nevertheless, no prospective study has 
compared the three therapeutic options yet, and the clinical 
utility of markers of hormone resistance such as AR splice 
variant 7 remains to be seen. A retrospective analysis based 
on data collected from several clinical trials of second-line 
hormonal therapy in patients with CRPC indicated that a 
longer-lasting response to previous hormonal treatment is a 
positive predictive factor for a response to either abiraterone, 
ketoconazole–hydrocortisone, bicalutamide or estrogens. 
Another retrospective study identified predictive factors for 
treatment response; patients who already underwent two or 
more lines of chemotherapy or those with a high Gleason 
score had less chance of being responsive to abiraterone. 
According to these data, it is reasonable to hypothesize that 
patients with a well-differentiated tumor, and especially those 
with a longer-lasting response to first-line hormonal therapy, 
have better results with new-generation endocrine agents.
The use of AR-directed therapies in earlier phases 
of treatment, or the combination of abiraterone and 
enzalutamide are being tested in larger trials. Attempts 
are made to increase the efficacy of docetaxel through 
combination with other agents such as antiVEGF molecules, 
vitamin D, lenalinomide, and endothelin antagonists, all of 
which failed to show survival benefit. One very interesting 
trial is comparing cabazitaxel 25 mg/m2 versus cabazitaxel 
20 mg/m2 versus standard first-line docetaxel chemotherapy 
(FIRSTANA; NCT01308567).
 A better understanding of new drug resistance 
mechanisms and prostate cancer molecular subtypes based 
on genomic and proteomic analysis, as well as prognostic 
and predictive biomarkers, may further improve mCRPC 
treatment. Future efforts have to be made in order to tie 
prostate cancer biology to therapy so as to maximize benefit 
and minimize toxicity and costs.
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